Malignant Pleural Effusion Treatment Outcomes: Pleurodesis via Video-Assisted Thoracic Surgery (VATS) Versus Tube Thoracostomy

Abstract

Study Objectives: Video-assisted thoracic surgery (VATS) has been widely used in the diagnosis and management of various thoracic diseases. The objective of this retrospective study was to compare the effectiveness of patients undergoing pleurodesis through VATS versus tube thoracostomy for malignant pleural effusion (MPE). Study design was a retrospective review of patients treated in medical centers and hospitals in Taiwan. Patients: One hundred and forty-eight patients with MPE resistant to systemic therapy resulting from various types of carcinomas were retrospectively reviewed. VATS pleurodesis was carried out in 82 and tube thoracostomy with pleurodesis in 66 patients. Results: There were no intraoperative deaths and 4 (2.7 %) in-hospital deaths. One hundred and eighteen (79.7 %) patients were available for follow-up. There were no statistically significant differences in the preoperative characteristics of the two treatment groups, except that the amount of effusion and the percentage of patients with dyspnea were both higher in the VATS treatment group. The duration of chest tube drainage was significantly longer (p < 0.01) in the tube thoracostomy treatment group (9.1 ± 3.3 vs. 6.2 ± 2.3 days). There were no significant differences between the treatment groups with regard to the incidence of surgical complications and perioperative mortality. Median survival was similar in both treatment groups; however, the VATS treatment group had a significantly longer median recurrence-free survival than the tube thoracostomy treatment group. Conclusions: VATS treatment for MPE appears to be superior to tube thoracostomy for diagnostic accuracy and effectiveness in preventing effusion recurrence; however, the role of these treatments for MPE is palliative, and does not significantly prolong survival time.

Key words

Thoracic surgery - heart and lung transplantation - heart disease

References

• 1 Marthay R A, Coppage L, Shaw C. et al . Malignancies metastatic to the pleura.  Invest Radiol. 1990;  25 601-619
• 2 Burrows C, Mathews C, Colt H. Predicting survival in patients with recurrent symptomatic malignant pleural effusions.  Chest. 2000;  117 73-78
• 3 Sahn A S. Malignancy metastatic to the pleura.  Clin Chest Med. 1998;  19 351-361
• 4 Wang P S, Goldstraw P. Pleuroperitoneal shunts: review.  Br J Hosp Med. 1993;  50 16-21
• 5 Daivies C, Traill Z, Gleeson F. et al . Intrapleural streptokinase in the management of malignant multiloculated pleural effusions.  Chest. 1999;  115 729-733
• 6 Belani C, Pajean T, Bennett C. Treating malignant pleural effusions cost consciously.  Chest. 1998;  113 78S-85S
• 7 Wissberg D, Ben-Zeev I. Talc pleurodesis. Experiences with 360 patients.  J Thorac Cardiovasc Surg. 1993;  106 678-695
• 8 Moragon E M, Aparico J, Sanchis J. et al . Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases.  Respir. 1998;  65 108-113
• 9 Toms A P, Tasker A, Flower C. Intervention in the pleura.  Eur J Radiol. 2000;  34 119-132
• 10 Patz E F. Malignant pleural effusions: Recent advances and ambulatory sclerotherapy.  Chest. 1998;  113 74S-77S
• 11 Erasmus J, Goodman P, Patz E. Management of malignant pleural effusions and pneumothorax.  Radiol Clin North Am. 2000;  38 375-383
• 12 Erasmus J, Patz E. Treatment of malignant pleural effusions.  Curr Opin Pulmon Med. 1999;  5 250-255
• 13 Light R W. Management of pleural effusions.  J Formos Med Assoc. 2000;  99 523-531
• 14 Erickson K V, Yost M, Bynoe R. et al . Primary treatment of malignant pleural effusions: Video-assisted thoracoscopic surgery poudrage versus tube thoracostomy.  Am Surg. 2002;  68 955-960
• 15 Anderson C B, Philpott G W, Ferguson T B. The treatment of malignant pleural effusion.  Cancer. 1974;  33 916-922
• 16 Grossi F, Penucci M C, Tixi L. et al . Management of malignant pleural effusions.  Drugs. 1998;  55 47-58
• 17 Keller S M. Current and future therapy for malignant pleural effusions.  Chest. 1993;  103 63-67
• 18 Yim A, Chung S, Lee T. et al . Thoracoscopic management of malignant pleural effusions.  Chest. 1996;  109 1234-1238
• 19 Danby C, Adebonojo S, Moritz D. Video-assisted talc pleurodesis for malignant pleural effusions utilizing local anesthesia and IV sedation.  Chest. 1998;  113 739-742
• 20 Hartman D, Gaither J, Kesler K. et al . Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions.  J Thorac Cardiovasc Surg. 1993;  105 743-748
• 21 Robinson G, Gleeson K. Diagnostic flexible fibroscopic pleuroscopy in suspected malignant pleural effusions.  Chest. 1995;  107 424-429
• 22 Viallat J, Rey F, Astoul P. et al . Thoracoscopic talc poudrage for malignant effusions: a review of 360 cases.  Chest. 1996;  110 1387-1393
• 23 Zimmer P, Hill M, Casey K. et al . Prospective randomized trial of talc slurry vs. bleomycin in pleurodesis for symptomatic malignant pleural effusions.  Chest. 1997;  112 430-434
• 24 Yim A, Chan A, Lee T. et al . Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion.  Ann Thorac Surg. 1997;  64 592-593
• 25 Crnjac A, Sok M, Kamenik M. Impact of pleural effusion pH on the efficacy of thoracoscopic mechanical pleurodesis in patients with breast carcinoma.  Eur J Cardiothorac Surg. 2004;  26 432-436